bnf mart

Zifam Sovir Plus

Add to Wishlist
SKU: B00740229
A+

1. Composition:
Each film coated tablet cont......

1. Composition:
Each film coated tablet contains:
Sofosbuvir …………………….. 400 mg
Ledipasvir …………………….. 90 mg
Excipients: q.s.


2. Therapeutic indication:
ZIFAM SOVIR PLUS is indicated tor the treatment of chronic hepatitis C (CHC) with or without cirrhosis in adults and in adolescent aged 12 to < 18 years (weight>/= 35kg).


3. Adverse effects:
The most common adverse reactions (incidence greater than or equal to 10% all grades) observed with treatment with ZIFAM SOVIR PLUS were fatigue, headache and asthenia. Adverse drug reactions to ZIFAM SOVIR PLUS + ribavirin combination therapy were consistent with the known safety profile of ribavirin, without increasing the frequency or severity of the expected adverse drug reactions. No new adverse drug reactions were detected among patients with decompensated cirrhosis and/or who were post-liver transplant and who received ledipasvir/sofosbuvir with ribavirin


This medicine is Prescription Only Medicine (POM ) and required under medical supervision.

ဤဆေးသည် POM ဆေးအုပ်စုတွင်ပါဝင်သောကြောင့် ဆရာဝန်ညွှန်ကြားချက်အတိုင်းသာ သုံးစွဲသင့်ပါသည်။

Read more

Size : 28 Tablet Bottle

Rated 5.00 out of 5 based on 1 customer rating
(0 customer review)
1 × 94,600 Ks

[ 1 × 94,600 Ks ]

Description

Zifam Sovir Plus

1. Composition:
Each film coated tablet contains:
Sofosbuvir …………………….. 400 mg
Ledipasvir …………………….. 90 mg
Excipients: q.s.


2. Therapeutic indication:
ZIFAM SOVIR PLUS is indicated tor the treatment of chronic hepatitis C (CHC) with or without cirrhosis in adults and in adolescent aged 12 to < 18 years (weight>/= 35kg).


3. Adverse effects:
The most common adverse reactions (incidence greater than or equal to 10% all grades) observed with treatment with ZIFAM SOVIR PLUS were fatigue, headache and asthenia. Adverse drug reactions to ZIFAM SOVIR PLUS + ribavirin combination therapy were consistent with the known safety profile of ribavirin, without increasing the frequency or severity of the expected adverse drug reactions. No new adverse drug reactions were detected among patients with decompensated cirrhosis and/or who were post-liver transplant and who received ledipasvir/sofosbuvir with ribavirin


This medicine is Prescription Only Medicine (POM ) and required under medical supervision.

ဤဆေးသည် POM ဆေးအုပ်စုတွင်ပါဝင်သောကြောင့် ဆရာဝန်ညွှန်ကြားချက်အတိုင်းသာ သုံးစွဲသင့်ပါသည်။

Reviews

0
0
0
0
0
0

Add a review